Priya Kunapuli

Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers

2

Total Citations

55

H-Index

2

About

Priya Kunapuli is a leading figure in the advancement of high-throughput screening (HTS) technologies, with a particular focus on cell-based functional assays and G protein-coupled receptor (GPCR) drug discovery. Her work has been instrumental in overcoming a critical bottleneck in HTS: the reliable supply of live cells for consistent, day-to-day screening operations. Her seminal 2005 paper on "Division Arrest Technology" (33 citations) demonstrated a novel method to halt cell division, enabling the use of a single, frozen cell batch for weeks of screening—a breakthrough that dramatically improved assay reproducibility and logistical efficiency. Building on this, Kunapuli pioneered ultra-high-throughput screening methods for GPCRs, a key target class in therapeutics. Her 2008 study (22 citations) detailed a 1,536-well [³⁵S]GTPγS scintillation proximity assay for orphan Gαi-coupled receptors, setting a new standard for sensitivity and throughput in GPCR drug discovery. By solving practical challenges in cell supply and assay miniaturization, Kunapuli’s contributions have directly accelerated the pace of pharmaceutical research, enabling more robust and scalable screens for novel drug candidates.

Research Focus

Key Achievements

2
H-Index
2
Papers
55
Total Citations
28
Avg Citations/Paper
🏆 Most Cited Paper
Application of Division Arrest Technology to Cell-Based HTS: Comparison with Frozen and Fresh Cells
33 citations · 2005
📈 Most Prolific Year: 2005 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago